###begin article-title 0
###xml 51 55 <span type="species:ncbi:10090">Mice</span>
Molecular Determinants of Ebola Virus Virulence in Mice
###end article-title 0
###begin p 1
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 0 16 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 60 66 <span type="species:ncbi:9606">humans</span>
###xml 113 119 <span type="species:ncbi:9606">humans</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 407 418 <span type="species:ncbi:205488">Ebola virus</span>
###xml 420 424 <span type="species:ncbi:205488">EBOV</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 971 975 <span type="species:ncbi:205488">EBOV</span>
###xml 1024 1028 <span type="species:ncbi:205488">EBOV</span>
Zaire ebolavirus (ZEBOV) causes severe hemorrhagic fever in humans and nonhuman primates, with fatality rates in humans of up to 90%. The molecular basis for the extreme virulence of ZEBOV remains elusive. While adult mice resist ZEBOV infection, the Mayinga strain of the virus has been adapted to cause lethal infection in these animals. To understand the pathogenesis underlying the extreme virulence of Ebola virus (EBOV), here we identified the mutations responsible for the acquisition of the high virulence of the adapted Mayinga strain in mice, by using reverse genetics. We found that mutations in viral protein 24 and in the nucleoprotein were primarily responsible for the acquisition of high virulence. Moreover, the role of these proteins in virulence correlated with their ability to evade type I interferon-stimulated antiviral responses. These findings suggest a critical role for overcoming the interferon-induced antiviral state in the pathogenicity of EBOV and offer new insights into the pathogenesis of EBOV infection.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 371 387 371 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 521 537 521 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 1240 1256 1240 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 1305 1321 1305 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 0 16 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 52 58 <span type="species:ncbi:9606">humans</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 371 387 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 521 537 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
###xml 938 942 <span type="species:ncbi:10090">mice</span>
###xml 1093 1098 <span type="species:ncbi:10090">mouse</span>
###xml 1240 1256 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 1305 1321 <span type="species:ncbi:186538">Zaire ebolavirus</span>
Zaire ebolavirus causes severe hemorrhagic fever in humans with up to 90% case-fatality rates. Currently, there are no vaccines or specific therapeutic interventions available for this devastating viral disease due, at least in part, to a lack of knowledge regarding the molecular basis of virulence for this extremely pathogenic agent. While adult mice resist wild-type Zaire ebolavirus infection, the virus has recently been adapted to cause lethal infection in mice. In order to understand the pathogenesis underlying Zaire ebolavirus infection, the authors identified the mutations responsible for the acquisition of virulence in mice, using reverse genetics technology, which allows the generation of genetically altered mutant viruses from cloned cDNA. By testing the virulence of mutant viruses, two viral proteins, viral protein 24 and the nucleoprotein, were found to be primarily responsible for the acquisition of virulence in mice. Moreover, the role of these proteins in virulence correlated with their ability to confer resistance to interferon-stimulated antiviral responses in mouse cells. These findings suggest a critical role of these proteins in overcoming the interferon-induced antiviral state in the pathogenicity of Zaire ebolavirus and offer new insights into the pathogenesis of Zaire ebolavirus infection.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zaire ebolavirus</italic>
###xml 49 60 49 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Filoviridae</italic>
###xml 68 79 68 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ebolavirus,</italic>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b001">1</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b003">3</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b004">4</xref>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b006">6</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b007">7</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b008">8</xref>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b009">9</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b010">10</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b004">4</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b006">6</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b011">11</xref>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b007">7</xref>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b009">9</xref>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b010">10</xref>
###xml 0 16 <span type="species:ncbi:186538">Zaire ebolavirus</span>
###xml 115 121 <span type="species:ncbi:9606">humans</span>
###xml 195 201 <span type="species:ncbi:9606">humans</span>
###xml 324 335 <span type="species:ncbi:205488">Ebola virus</span>
###xml 337 341 <span type="species:ncbi:205488">EBOV</span>
###xml 525 529 <span type="species:ncbi:205488">EBOV</span>
Zaire ebolavirus (ZEBOV), a member of the family Filoviridae, genus Ebolavirus, causes severe hemorrhagic fever in humans and nonhuman primates (NHPs). Case-fatality rates for ZEBOV infection in humans are the highest among known viral hemorrhagic fevers, ranging from 70% to 90% [1-3]. On the basis of in vitro data, three Ebola virus (EBOV) proteins, the glycoprotein (GP) [4-6], the membrane-associated viral protein (VP) 24 [7,8], and VP35 [9,10], a component of the replication complex, are thought to play key roles in EBOV pathogenicity. The GP, which mediates viral entry, is a major determinant of viral tropism and may be cytotoxic, although a recent report has challenged the notion of GP's cytotoxicity [4-6,11]. VP24 and VP35 are known as type I interferon (IFN) antagonists and interfere with the type I IFN-mediated antiviral response in vitro [7,9,10]. However, the role of these proteins in viral pathogenicity has not been determined in vivo.
###end p 5
###begin p 6
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b012">12</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b014">14</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b014">14</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b014">14</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b002">2</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b015">15</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b017">17</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b015">15</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b018">18</xref>
###xml 1214 1216 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b019">19</xref>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b021">21</xref>
###xml 27 38 <span type="species:ncbi:10141">guinea pigs</span>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 74 78 <span type="species:ncbi:205488">EBOV</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
###xml 634 640 <span type="species:ncbi:9606">humans</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:205488">EBOV</span>
###xml 841 847 <span type="species:ncbi:9606">humans</span>
###xml 930 935 <span type="species:ncbi:10090">mouse</span>
###xml 990 995 <span type="species:ncbi:10090">mouse</span>
###xml 1040 1045 <span type="species:ncbi:9606">human</span>
Three animal models, NHPs, guinea pigs, and mice, have been used to study EBOV pathogenesis [12-14]. Generally, filoviruses do not kill adult immunocompetent rodents, although some strains have been shown to cause lethal infections in newborn mice [14]. Bray et al. [14] adapted ZEBOV to progressively older BALB/c mice and thereby established a lethal model in adult immunocompetent mice. Infection of mice with mouse-adapted virus (MA-ZEBOV) involves primary target cells of the mononuclear phagocytic system, namely monocytes, macrophages, and dendritic cells, as well as target organs (spleen, lymph nodes, and liver), as seen in humans and NHPs, resulting in a disease comparable to that observed in the latter animals [2,15-17]. Although MA-ZEBOV-infected mice do not exhibit coagulation abnormalities, a hallmark of EBOV infection in humans and NHPs, this is understandable given that coagulopathy is not generally seen in mouse models for acute viral infections [15,18]. Thus, this mouse model may not exactly mirror all aspects of human Ebola hemorrhagic fever; however, it does provide a relevant and convenient animal model with which to study aspects of pathogenicity and host immune response in vivo [19-21].
###end p 6
###begin p 7
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b022">22</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b023">23</xref>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:205488">EBOV</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 429 434 <span type="species:ncbi:10090">mouse</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
The adaptation of ZEBOV to adult mice resulted in a number of nucleotide changes in both the coding and noncoding regions (NCRs) of the virus genome [22]. To identify the molecular features that determine EBOV virulence in mice, here, we exploited a reverse genetics system to generate infectious ZEBOV entirely from cloned cDNA [23] and artificially generate recombinant viruses possessing various combinations of wild-type and mouse-adapted genes. The virulence of these recombinant viruses was then tested in adult immunocompetent mice.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
Construction and Generation of Recombinant MA-ZEBOV Mutants from cDNAs
###end title 9
###begin p 10
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b014">14</xref>
###xml 573 581 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">Figure 1</xref>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">1</xref>
###xml 949 957 949 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">Figure 1</xref>
###xml 963 964 963 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">1</xref>
###xml 1025 1033 1025 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">Figure 1</xref>
###xml 1039 1040 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">1</xref>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 678 683 <span type="species:ncbi:10090">mouse</span>
The ZEBOV variant that served as the starting point for adaptation in mice (referred to as precursor mouse-adapted virus [pre-MA-ZEBOV]) differed from the published sequence of the wild-type ZEBOV (WT-ZEBOV), strain Mayinga, in four nucleotide positions. These mutations may have been acquired during three consecutive passages in the brains of newborn mice and/or two passages in Vero E6 cells [14]. Three of these mutations resulted in amino acid changes in the glycoprotein (GP), while the fourth created a silent mutation in the open reading frame (ORF) encoding VP40 (Figure 1A and 1B). Serial passage of pre-MA-ZEBOV in progressively older suckling mice yielded the fully mouse-adapted variant (MA-ZEBOV), which possessed nine additional nucleotide changes. Nucleotide substitutions leading to amino acid changes were found in VP35, VP24, nucleoprotein (NP) (one amino acid change each), and the polymerase protein L (two amino acid changes) (Figure 1A and 1B). An additional two nucleotide changes were found in NCRs (Figure 1A and 1B), which may affect replication and/or transcription efficiencies. The remaining two nucleotide modifications, in the NP and L genes, were silent.
###end p 10
###begin p 11
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b023">23</xref>
###xml 200 208 200 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">Figure 1</xref>
###xml 347 355 347 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g001">Figure 1</xref>
###xml 485 493 485 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 540 545 <span type="species:ncbi:10090">mouse</span>
Using a reverse genetics system to create ZEBOV from plasmid DNAs [23], we generated MA-RG (mouse-adapted reverse genetics virus) by introducing all but three mutations into the backbone of WT-ZEBOV (Figure 1B). MA-RG differed from MA-ZEBOV by the three silent mutations in the NP, VP40, and L ORFs that were introduced during adaptation in mice (Figure 1B). We also generated a variety of recombinant viruses containing various subsets of the mutations found in MA-ZEBOV (depicted in Figure 2A) to identify those mutations responsible for mouse adaptation.
###end p 11
###begin title 12
###xml 51 55 <span type="species:ncbi:10090">Mice</span>
The VP24 and NP Genes Determine ZEBOV Virulence in Mice
###end title 12
###begin p 13
###xml 382 390 382 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 438 440 438 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 765 767 765 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 774 776 774 776 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 1095 1103 1095 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 1131 1133 1131 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1234 1236 1234 1236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1302 1310 1302 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 1483 1485 1483 1485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 1565 1567 1565 1567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 1574 1576 1574 1576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 833 837 <span type="species:ncbi:10090">mice</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 1158 1162 <span type="species:ncbi:10090">mice</span>
###xml 1373 1378 <span type="species:ncbi:10090">mouse</span>
###xml 1596 1600 <span type="species:ncbi:10090">mice</span>
###xml 1738 1742 <span type="species:ncbi:10090">mice</span>
To identify the genetic determinants of ZEBOV virulence in mice, we inoculated groups of BALB/c mice (5 to 6 wk old; three to six per group) intraperitoneally (i.p.) with 10 focus-forming units (FFU) of WT-ZEBOV, the original mouse-adapted virus (MA-ZEBOV), its counterpart generated using reverse genetics (MA-RG), or viruses containing subsets of the mutations found in MA-ZEBOV (Figure 2A). This dose (10 FFU) corresponded to 1,000 MLD50 (the amount of virus required to kill 50% of the mice) for MA-ZEBOV. As expected, infection of mice with WT-ZEBOV did not produce a lethal infection or any clinical symptoms, unlike infection with either MA-ZEBOV or MA-RG. Interestingly, viruses containing the wild-type NP or VP24 genes in the background of MA-ZEBOV (MA-NPWT, MA-24WT) did not cause lethal infection or clinical symptoms in mice, suggesting a critical role for mutations in these proteins with respect to the virulence of MA-ZEBOV in mice. In contrast, substitution of the VP35, GP, and/or L genes of MA-RG with those of WT-ZEBOV did not dramatically reduce the virulence of the virus (Figure 2A). Determination of the MLD50, by i.p. inoculation of mice with 10-fold serial dilutions of viruses, revealed almost identical MLD50 values for all of these recombinant viruses with few exceptions (Figure 2A). We, therefore, tested the inverse genotypes by introducing mouse-adapted NP and VP24 genes, separately and in combination, into the background of WT-ZEBOV. Only WT-NP/24MA resulted in a lethal phenotype; neither of the single gene introductions (WT-NPMA, WT-24MA) caused disease in mice. These findings identified the specific amino acid changes in NP and VP24 that are the critical determinants of ZEBOV virulence in adult mice.
###end p 13
###begin title 14
###xml 67 71 <span type="species:ncbi:10090">Mice</span>
Multiple Mutations in MA-ZEBOV Contribute to Enhanced Virulence in Mice
###end title 14
###begin p 15
###xml 252 260 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 408 410 408 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 415 420 <span type="species:ncbi:10090">mouse</span>
All mice infected with virulent viruses displayed the same clinical symptoms (ruffled fur, decreased activity, and weight loss), but notable differences were observed in the mean time to death and in the dose ranges that caused morbidity or mortality (Figure 2B). Infection with MA-ZEBOV resulted in the shortest mean time to death, with lethal infection induced by a broad range of inoculum doses (105 to 10-3 FFU/mouse). The artificially generated MA-RG virus was slightly attenuated, suggesting that the silent mutations in the NP, VP40, and L genes, by which this mutant differs from MA-ZEBOV, may make a minor contribution to virulence.
###end p 15
###begin p 16
###xml 108 110 108 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 353 356 353 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> MA</sub>
###xml 377 379 377 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 685 687 685 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 702 704 702 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
###xml 655 660 <span type="species:ncbi:10090">mouse</span>
Similarly, the introduction of the mouse-adapted NP and VP24 genes into the background of WT-ZEBOV (WT-NP/24MA) did not bestow on WT-ZEBOV the fully pathogenic phenotype, as demonstrated by a prolonged time to death and a narrower dose range causing mortality than that of MA-ZEBOV. Insertion of the mutation into the 5' NCR of the VP24 gene of WT-NP/24 MA (i.e., WT-NP/24nc/24MA) reduced the time to death but did not appreciably expand the dose range for morbidity/mortality, indicating a rather minor contribution of this mutation to virulence in mice. In contrast, the nucleotide substitution in the 3' NCR of VP30 caused a more appreciable effect on mouse virulence (compare MA-GPWT and MA-GP/30ncWT, which differ only in the VP30 NCR).
###end p 16
###begin p 17
###xml 103 105 103 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 112 114 112 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 301 303 301 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
Single gene replacements of the mouse-adapted VP35, GP, or L with their wild-type counterparts (MA-VP35WT, MA-GPWT MA-LWT) led to different degrees of attenuation, indicating that all of the mutations contributed to some extent to the virulence of MA-ZEBOV in adult mice. Of these mutant viruses, MA-LWT showed the most pronounced attenuation, indicating that the two amino acid changes in the L protein of MA-ZEBOV are more critical for virulence in mice than those in the VP35 or GP proteins.
###end p 17
###begin title 18
###xml 26 31 <span type="species:ncbi:10090">Mouse</span>
Growth Characteristics in Mouse Organs
###end title 18
###begin p 19
###xml 154 162 154 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g003">Figure 3</xref>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g003">Figure 3</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g003">3</xref>
###xml 565 567 565 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 578 580 578 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 592 594 592 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 670 678 670 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">2</xref>
###xml 839 841 839 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 848 850 848 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:205488">EBOV</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 516 521 <span type="species:ncbi:10090">mouse</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
We next compared the growth characteristics of representative mutant viruses in mice infected with 5 FFU of virus by examining viral titers in the serum (Figure 3A) and in two target organs of EBOV, the spleen and liver (Figure 3B and 3C). As expected, WT-ZEBOV replicated poorly in mice, whereas the virus titers of MA-RG were the highest in all organs tested, again demonstrating that the full set of mutations is required to establish the fully pathogenic phenotype. Efficient virus replication required both the mouse-adapted NP and VP24 genes (compare WT-NP/24MA with WT-NPMA and WT-VP24MA), a finding that correlated well with virulence, as measured by lethality (Figure 2A and 2B). Likewise, the introduction of either the wild-type NP or VP24 gene into the background of MA-ZEBOV attenuated the resulting recombinant viruses (MA-NPWT, MA-24WT), further emphasizing the critical role of these mutations for viral replication in mice.
###end p 19
###begin title 20
Do Mutations in VP24 and NP Affect Virus Sensitivity to IFN?
###end title 20
###begin p 21
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b024">24</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b025">25</xref>
###xml 269 271 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b025">25</xref>
###xml 390 391 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b007">7</xref>
###xml 392 394 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b026">26</xref>
###xml 717 725 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g004">Figure 4</xref>
###xml 841 849 827 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g004">Figure 4</xref>
###xml 913 921 899 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g004">Figure 4</xref>
###xml 966 974 952 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g004">Figure 4</xref>
###xml 1314 1316 1300 1302 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 1459 1461 1445 1447 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 1472 1474 1458 1460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 1522 1524 1508 1510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 1539 1541 1525 1527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 137 141 <span type="species:ncbi:205488">EBOV</span>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 253 257 <span type="species:ncbi:205488">EBOV</span>
###xml 304 308 <span type="species:ncbi:205488">EBOV</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 694 700 <span type="species:ncbi:10090">murine</span>
###xml 1127 1131 <span type="species:ncbi:10090">mice</span>
###xml 1262 1267 <span type="species:ncbi:10090">mouse</span>
###xml 1826 1830 <span type="species:ncbi:205488">EBOV</span>
###xml 1879 1885 <span type="species:ncbi:9606">humans</span>
###xml 1934 1939 <span type="species:ncbi:10090">mouse</span>
The suppression of viral multiplication by type I IFN-mediated antiviral responses has been demonstrated in many viruses [24], including EBOV [25]. In fact, it is abrogation of the type I IFN (IFN-alpha/beta) system that makes adult mice susceptible to EBOV infection [25]. We and others have identified EBOV VP24 as being instrumental in this function (i.e., in inhibiting IFN signaling) [7,26]. To determine whether the amino acid changes in the VP24 and NP proteins of MA-ZEBOV facilitate evasion of the type I IFN-induced antiviral response, we compared virus growth of selected recombinant viruses in a mouse peritoneal macrophage cell line (RAW 264.7 cells) in the absence or presence of murine IFN-alpha/beta (Figure 4). WT-ZEBOV grew in nonstimulated cells, albeit to lower titers compared to the growth of the other viruses tested (Figure 4A); however, in cells stimulated with IFN at 2 h postinfection (Figure 4B) or 12 h prior to and 2 h after infection (Figure 4C), virus replication was severely reduced. In contrast, MA-RG grew to much higher titers even in IFN-stimulated cells, suggesting that its virulence in mice is linked to its ability to counteract IFN-induced antiviral responses. This ability clearly correlated with the mutations in the mouse-adapted VP24 and NP genes. In fact, WT-NP/VP24MA grew more efficiently in IFN-stimulated cells than did MA-RG, for unknown reasons. In cells that were stimulated with IFN postinfection, WT-NPMA or WT-VP24MA grew better than WT-ZEBOV. In contrast, WT-VP24MA, but not WT-NPMA, failed to replicate efficiently in cells treated with IFN prior to and after infection. These data indicate that the ability to counteract IFN-induced antiviral responses is responsible for the high virulence of MA-ZEBOV in this animal model and that IFN evasion may be critical for EBOV virulence in other animal models, as well as in humans. In addition, our findings show that while both mouse-adapted VP24 and NP provide the virus with the ability to counteract the IFN-induced antiviral responses, NP may be more critical for this effect in vitro. The concerted actions of both mutations, however, appear necessary for evading IFN-induced antiviral responses in vivo.
###end p 21
###begin title 22
Discussion
###end title 22
###begin p 23
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 475 481 <span type="species:ncbi:9606">humans</span>
In this study, we have identified molecular determinants of ZEBOV virulence in mice by using reverse genetics. We found VP24 and NP to be the primary determinants for adaptation of WT-ZEBOV in mice and found a correlation between virulence and the ability of the virus to evade the type I IFN-induced antiviral response. The ability to overcome the IFN-induced antiviral response is, therefore, a critical event in the pathogenesis of ZEBOV infection in mice and possibly in humans. Moreover, mutations in other viral proteins and NCRs also contribute to the virulent phenotype, indicating that virulence is a multifactor trait.
###end p 23
###begin p 24
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b007">7</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b026">26</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b027">27</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b028">28</xref>
###xml 737 745 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g004">Figure 4</xref>
###xml 863 865 863 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MA</sub>
###xml 633 638 <span type="species:ncbi:10090">mouse</span>
###xml 1216 1220 <span type="species:ncbi:10090">mice</span>
Recent in vitro studies suggest that VP24 functions as a type I IFN antagonist [7,26], but the significance of this finding had not been addressed in vivo until now. Here, we have demonstrated that single amino acid modifications in VP24 and NP of MA-ZEBOV are critical for virus evasion of IFN-induced antiviral responses. NP has not previously been considered as a potential IFN antagonist. However, given that it interacts with VP24 in the formation of nucleocapsids [27,28], it is not unreasonable to imagine that it may act as an enhancer and/or stabilizer of VP24 functions. Nevertheless, since the NP mutation acquired during mouse adaptation of WT-ZEBOV alone allowed the recombinant virus to replicate in IFN-treated cells (see Figure 4C), NP likely plays a more direct role in the evasion of the IFN-induced antiviral response. Interestingly, WT-NP/VP24MA grew more efficiently than MA-RG in IFN-stimulated cells, in contrast to our in vivo results. For this reason, it seems likely that the mutations in VP24 and NP are critical for resistance to IFN-induced antiviral responses, while the remaining mutations acquired during adaptation of WT-ZEBOV facilitate efficient virus replication and/or spread in mice despite their attenuated phenotype in cell culture systems.
###end p 24
###begin p 25
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b004">4</xref>
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b006">6</xref>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b009">9</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b010">10</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b009">9</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b010">10</xref>
###xml 389 397 389 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b005">5</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b029">29</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b030">30</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b011">11</xref>
###xml 43 47 <span type="species:ncbi:205488">EBOV</span>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
###xml 525 529 <span type="species:ncbi:205488">EBOV</span>
###xml 572 576 <span type="species:ncbi:205488">EBOV</span>
VP35 and GP have previously been linked to EBOV pathogenicity [4-6,9,10]. VP35 is an IFN antagonist that interferes with type I IFN synthesis by inhibiting IRF-3 (interferon regulatory factor 3) activation, a necessary step for the transcription of IFN genes [9,10]. Although the mutation found in the mouse-adapted VP35 protein was not responsible for the enhanced virulence of MA-ZEBOV (Figure 2B), this does not necessarily indicate that VP35-mediated regulation of IFN levels does not play a part in the pathogenicity of EBOV. This activity may still be important for EBOV to achieve high virulence. Likewise, GP is cytotoxic and is, therefore, thought to contribute to viral pathogenicity [5,29,30]. However, a recent report suggested that this cytotoxicity originated from overexpression of GP in cells [11]. As with VP35, the lack of an adaptive mutation in the GP of MA-ZEBOV does not necessarily diminish the role of GP in viral pathogenicity.
###end p 25
###begin p 26
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b008">8</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b031">31</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b032">32</xref>
###xml 42 53 <span type="species:ncbi:10141">guinea pigs</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
Interestingly, the adaptation of ZEBOV in guinea pigs also resulted in amino acid changes in NP, VP24, and L and in a nucleotide substitution in the VP30 NCR [8]. Although these mutations differed in their amino acid positions from those in MA-ZEBOV, it seems likely that they serve a similar role in adaptation and also function by counteracting innate antiviral responses [31,32]. As with mice, additional mutations (e.g., in L and the VP30 NCR) likely contribute to virulence by affecting viral transcription/replication.
###end p 26
###begin p 27
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b015">15</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b018">18</xref>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b018">18</xref>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 987 992 <span type="species:ncbi:10090">mouse</span>
###xml 1141 1146 <span type="species:ncbi:10090">mouse</span>
###xml 1268 1274 <span type="species:ncbi:9606">humans</span>
The mouse model using MA-ZEBOV does not exactly mirror all aspects of human Ebola hemorrhagic fever [15,18]. Thus, determinants for virulence of ZEBOV may differ between mouse and primate models. However, since ZEBOV is naturally lethal to primates, but not to mice, this model provided an opportunity to decipher the roles of viral proteins in expression of high virulence in a host (i.e., mice). Our studies showed that ZEBOV VP24 and NP are inadequate for the expression of high virulence in mice, but upon mutation, optimally expressed this property. Thus, it is possible that these viral proteins play an important role in expression of high virulence in primates. Likewise, the lack of VP35 mutations correlating with pathogenicity in mice is interesting, indicating that ZEBOV VP35 optimally functions in both primates and mice without additional mutation in an IFN pathway. Since MA-ZEBOV is attenuated in NHPs [18], one or more genes into which mutations were introduced during mouse adaptation of ZEBOV likely play a role in virulence in primates. Therefore, it will be interesting to examine the virulence of selected recombinant mouse-adapted variants in NHPs. Such studies will provide us with valuable information for understanding ZEBOV pathogenesis in humans.
###end p 27
###begin p 28
###xml 93 101 93 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b033">33</xref>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 146 151 <span type="species:ncbi:10090">mouse</span>
###xml 162 174 <span type="species:ncbi:11292">rabies virus</span>
###xml 463 467 <span type="species:ncbi:205488">EBOV</span>
Of note, we observed resistance in mice to infection with high infectious doses of MA-ZEBOV (Figure 2B). A similar finding has been observed in a mouse model for rabies virus [33]. The most likely explanation for this finding is that inoculation with high doses of virus causes a rapid stimulation of the innate immune response before virus replication or spread can occur. This topic presents an attractive research subject that may lead to control measures for EBOV infections through immunologic modulation of host responses to viral infection.
###end p 28
###begin p 29
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b034">34</xref>
###xml 138 142 <span type="species:ncbi:205488">EBOV</span>
###xml 194 199 <span type="species:ncbi:10090">mouse</span>
###xml 292 296 <span type="species:ncbi:205488">EBOV</span>
###xml 530 534 <span type="species:ncbi:205488">EBOV</span>
In conclusion, the combination of reverse genetics technology [34] and a small-animal model has allowed us to gain valuable insights into EBOV pathogenesis. Understanding the molecular basis of mouse adaptation of ZEBOV will likely lead to the identification of viral genetic determinants of EBOV virulence and to the elucidation of the roles of specific viral proteins in the pathogenic process. A more detailed molecular understanding of virulence and the host responses will also be crucial to improving our ability to control EBOV infections in the future.
###end p 29
###begin title 30
Materials and Methods
###end title 30
###begin title 31
Cells.
###end title 31
###begin p 32
###xml 184 185 184 185 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 294 295 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 9 29 <span type="species:ncbi:9534">African green monkey</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
Vero E6 (African green monkey kidney) cells, 293T (human embryonic kidney) cells, and RAW 264.7 cells (mouse peritoneal macrophages) were grown in DMEM supplemented with 10% FBS, 2 mM l-glutamine, and penicillin (100 U/ml)-streptomycin (100 mug/ml). Cells were incubated at 37 degreesC in 5% CO2.
###end p 32
###begin title 33
Generation of mutant Ebola viruses.
###end title 33
###begin p 34
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b023">23</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b023">23</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b023">23</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b035">35</xref>
###xml 394 398 <span type="species:ncbi:205488">EBOV</span>
Starting with a cDNA clone encoding WT-ZEBOV, strain Mayinga [23], we introduced stepwise mutations to reproduce MA-ZEBOV, using PCR-based mutagenesis. The resulting plasmids, which are flanked by T7 RNA polymerase promoter and ribozyme sequences [23], were cotransfected into a mixed culture of Vero E6 and 293T cells, together with helper plasmids for the expression of T7 RNA polymerase and EBOV NP, VP35, VP30, and L (required components of the viral replication complex), following established protocols [23,35]. All viruses were amplified once in Vero E6 cells. DMEM supplemented with 2% FBS was used to prepare virus stocks.
###end p 34
###begin p 35
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b036">36</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b037">37</xref>
###xml 185 189 <span type="species:ncbi:205488">EBOV</span>
###xml 233 239 <span type="species:ncbi:9986">rabbit</span>
###xml 276 280 <span type="species:ncbi:9925">goat</span>
###xml 286 292 <span type="species:ncbi:9986">rabbit</span>
Virus infectivity titers (FFU) were obtained by counting the number of infected cell foci detected by use of an indirect immunofluorescent antibody assay, as previously described [36]. EBOV antigen-positive foci were detected with a rabbit polyclonal anti-VP40 antibody and a goat anti-rabbit IgG-FITC conjugate [37].
###end p 35
###begin title 36
Animal experiments.
###end title 36
###begin p 37
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
Five- to 6-wk-old female BALB/c mice were obtained from a commercial supplier (Charles River Laboratories, Wilmington, Massachusetts, United States). All mice were housed in microisolator cages and allowed to acclimatize for 5 days prior to use in experiments.
###end p 37
###begin p 38
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
To assay virulence, groups of three to six mice were each inoculated i.p. at two different sites with 10 FFU of virus in 0.1 ml of DMEM. Following infection, mice were observed daily for clinical symptoms and their weights were recorded for 11 d postinoculation. All surviving animals were observed for at least 21 d (three times the average duration of survival of the control animals).
###end p 38
###begin p 39
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
The MLD50 was determined by i.p. inoculation of mice (three to six per group) with serial 10-fold dilutions of virus and monitoring of the survival rates.
###end p 39
###begin p 40
###xml 147 149 147 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b036">36</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
To assess virus growth characteristics in mice, groups of 12 animals were inoculated i.p. with 5 FFU of virus (corresponds to approximately 500 MLD50 for MA-ZEBOV). On days 1, 2, 3, and 5 postinfection, spleen, liver, and blood were collected from three infected mice, and the spleen and liver samples were homogenized. Viral infectivity titers were determined by use of a focus-forming assay in Vero E6 cells [36].
###end p 40
###begin p 41
###xml 19 23 <span type="species:ncbi:205488">EBOV</span>
All work with live EBOV was performed in the BSL-4 laboratory of the National Microbiology Laboratory of the Public Health Agency of Canada. All animal experiments were performed in accordance with approved animal use documents and according to the guidelines of the Canadian Council on Animal Care.
###end p 41
###begin title 42
###xml 39 45 <span type="species:ncbi:10090">murine</span>
Replication kinetics in IFN-stimulated murine cells.
###end title 42
###begin p 43
###xml 419 421 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b036">36</xref>
###xml 164 170 <span type="species:ncbi:10090">murine</span>
RAW 264.7 cells were infected with the respective viruses at a multiplicity of infection of 0.05. The cells were either left untreated or treated with 500 units/ml murine IFN-alpha/beta 2 h postinfection, or 12 h prior to infection and again 2 h postinfection. For all samples, virus titers in the supernatants were determined on days 0, 1, 2, 3, and 4 postinfection by use of the focus-forming assay in Vero E6 cells [36]. The first sample (day 0) was collected after the virus had adsorbed and the cell monolayer had been washed three times.
###end p 43
###begin title 44
Statistical analyses.
###end title 44
###begin p 45
###xml 87 89 85 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 99 107 97 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020073-g002">Figure 2</xref>
###xml 148 149 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 211 212 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
All virus titers in the growth kinetics experiments are shown as the mean +/- SEM. The p-values in Figure 2B were calculated by using the Student's t-test (two-tailed distribution, two-sample unequal variance). p < 0.05 was considered to indicate statistical significance.
###end p 45
###begin title 46
Supporting Information
###end title 46
###begin title 47
Accession Numbers
###end title 47
###begin p 48
The GenBank accession numbers for the genes mentioned in this paper are WT-ZEBOV, strain Mayinga (AF086833) and MA-ZEBOV variant (AF499101).
###end p 48
###begin p 49
The authors thank D. Dick, F. Feldmann, L. Fernando, and A. Paille for assistance with BSL-4 procedures; M. McGregor and K. Wells for technical assistance; and S. Watson and A. Groseth for editing the manuscript.
###end p 49
###begin p 50
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. HE and YK conceived and designed the experiments. HE, AT, DK, SJ, ST, and HF performed the experiments in BSL-4 containment. HE and GN performed the cloning experiments. HE, AT, HF, and YK analyzed the data. MB contributed materials and information. HE, AT, GN, HF, and YK wrote the manuscript.
###end p 50
###begin title 51
Abbreviations
###end title 51
###begin p 52
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus
###end p 52
###begin p 53
focus-forming units
###end p 53
###begin p 54
interferon
###end p 54
###begin p 55
intraperitoneal
###end p 55
###begin p 56
###xml 0 5 <span type="species:ncbi:10090">mouse</span>
mouse-adapted reverse genetics virus
###end p 56
###begin p 57
###xml 0 5 <span type="species:ncbi:10090">mouse</span>
mouse-adapted virus
###end p 57
###begin p 58
###xml 44 48 <span type="species:ncbi:10090">mice</span>
amount of virus required to kill 50% of the mice
###end p 58
###begin p 59
noncoding region
###end p 59
###begin p 60
nonhuman primate
###end p 60
###begin p 61
nucleoprotein
###end p 61
###begin p 62
open reading frame
###end p 62
###begin p 63
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
precursor virus for generating mouse-adapted virus
###end p 63
###begin p 64
viral protein
###end p 64
###begin p 65
wild-type virus
###end p 65
###begin p 66
###xml 0 16 <span type="species:ncbi:186538">Zaire ebolavirus</span>
Zaire ebolavirus
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
###xml 31 42 <span type="species:ncbi:205488">Ebola virus</span>
Filoviridae: Marburg virus and Ebola virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Malcolm AM, et al., editors. Field's virology. 4th edition. Philadelphia: Lippincott Williams & Wilikins. pp. 1279-1304
###end article-title 68
###begin article-title 69
Exotic emerging viral diseases: Progress and challenges
###end article-title 69
###begin article-title 70
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus: From discovery to vaccine
###end article-title 70
###begin article-title 71
###xml 33 44 <span type="species:ncbi:205488">Ebola virus</span>
The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis
###end article-title 71
###begin article-title 72
Biosynthesis and role of filoviral glycoproteins
###end article-title 72
###begin article-title 73
###xml 11 22 <span type="species:ncbi:205488">Ebola virus</span>
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function
###end article-title 73
###begin article-title 74
Modulation of innate immunity by filoviruses
###end article-title 74
###begin article-title 75
###xml 30 40 <span type="species:ncbi:10141">guinea pig</span>
###xml 61 72 <span type="species:ncbi:205488">Ebola virus</span>
Molecular characterization of guinea pig-adapted variants of Ebola virus
###end article-title 75
###begin article-title 76
###xml 4 15 <span type="species:ncbi:205488">Ebola virus</span>
The Ebola virus VP35 protein functions as a type I IFN antagonist
###end article-title 76
###begin article-title 77
###xml 4 15 <span type="species:ncbi:205488">Ebola virus</span>
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3
###end article-title 77
###begin article-title 78
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level
###end article-title 78
###begin article-title 79
Pathogenesis of Ebola hemorrhagic fever in primate models: Evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells
###end article-title 79
###begin article-title 80
###xml 29 40 <span type="species:ncbi:205488">Ebola virus</span>
###xml 54 65 <span type="species:ncbi:10141">guinea pigs</span>
Pathogenesis of experimental Ebola virus infection in guinea pigs
###end article-title 80
###begin article-title 81
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
###end article-title 81
###begin article-title 82
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions
###end article-title 82
###begin article-title 83
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection
###end article-title 83
###begin article-title 84
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice
###end article-title 84
###begin article-title 85
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 61 72 <span type="species:ncbi:10141">guinea-pigs</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus
###end article-title 85
###begin article-title 86
###xml 32 43 <span type="species:ncbi:205488">Ebola virus</span>
CD8-mediated protection against Ebola virus infection is perforin dependent
###end article-title 86
###begin article-title 87
###xml 26 37 <span type="species:ncbi:205488">Ebola virus</span>
Persistent infection with Ebola virus under conditions of partial immunity
###end article-title 87
###begin article-title 88
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 47 58 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus-like particles protect from lethal Ebola virus infection
###end article-title 88
###begin article-title 89
Vaccine research efforts for filoviruses
###end article-title 89
###begin article-title 90
###xml 65 76 <span type="species:ncbi:205488">Ebola virus</span>
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture
###end article-title 90
###begin article-title 91
Inverse interference: How viruses fight the interferon system
###end article-title 91
###begin article-title 92
###xml 64 68 <span type="species:ncbi:10090">mice</span>
The role of the type I interferon response in the resistance of mice to filovirus infection
###end article-title 92
###begin article-title 93
###xml 32 43 <span type="species:ncbi:205488">Ebola virus</span>
Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography
###end article-title 93
###begin article-title 94
###xml 16 27 <span type="species:ncbi:205488">Ebola virus</span>
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein
###end article-title 94
###begin article-title 95
Roles of filoviral matrix and glycoproteins in the viral life cycle
###end article-title 95
###begin article-title 96
###xml 22 33 <span type="species:ncbi:205488">Ebola virus</span>
Identification of the Ebola virus protein as the main viral determinant of vascular cell cytotoxicity and injury
###end article-title 96
###begin article-title 97
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 25 36 <span type="species:ncbi:10141">guinea pigs</span>
Ebola virus infection in guinea pigs: Presumable role of granulomatous inflammation in pathogenesis
###end article-title 97
###begin article-title 98
###xml 37 48 <span type="species:ncbi:205488">Ebola virus</span>
Elaboration of laboratory strains of Ebola virus and study of pathophysiological reactions of animals inoculated with these strains
###end article-title 98
###begin article-title 99
###xml 33 45 <span type="species:ncbi:11292">rabies virus</span>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Temperature-sensitive mutants of rabies virus in mice: A mutant (ts2) revertant mixture selectively pathogenic by the peripheral route of inoculation
###end article-title 99
###begin article-title 100
The role of reverse genetics systems in studying viral hemorrhagic fevers
###end article-title 100
###begin article-title 101
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus VP40 late domains are not essential for viral replication in cell culture
###end article-title 101
###begin article-title 102
###xml 17 30 <span type="species:ncbi:11599">Hantaan virus</span>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Pathogenicity of Hantaan virus in newborn mice: Genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence
###end article-title 102
###begin article-title 103
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus VP40-induced particle formation and association with the lipid bilayer
###end article-title 103
###begin title 104
Figures and Tables
###end title 104
###begin title 105
###xml 34 39 <span type="species:ncbi:10090">Mouse</span>
Molecular Differences among ZEBOV Mouse-Adapted Variants
###end title 105
###begin p 106
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b014">14</xref>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
(A) Comparison of ZEBOV variants. Pre-MA-ZEBOV differs from wild-type ZEBOV (WT-ZEBOV) by three amino acids in the GP (red triangles) and a silent mutation in the ORF of the VP40 gene (gray triangle). Serial passage of pre-MA-ZEBOV in progressively older mice yielded MA-ZEBOV [14], which contains coding changes in the NP, VP35, VP24, and polymerase (L) (all shown in red triangles). Two nucleotide changes localize to the NCRs at the 3' end of the VP30 and the 5' end of the VP24 gene (red triangles); the remaining three modifications in the NP, VP40, and L ORFs are silent (gray triangles).
###end p 106
###begin p 107
###xml 230 234 <span type="species:ncbi:10090">mice</span>
(B) Nucleotide and amino acid differences among WT-ZEBOV, pre-MA-ZEBOV, MA-ZEBOV, and MA-RG. The nucleotide changes in GP of pre-MA-ZEBOV, compared to WT-ZEBOV, as well as the changes acquired during adaptation of pre-MA-ZEBOV in mice are shown in red.
###end p 107
###begin p 108
-, no change.
###end p 108
###begin title 109
###xml 43 47 <span type="species:ncbi:10090">Mice</span>
Genetic Determinants of Virulence in Adult Mice
###end title 109
###begin p 110
###xml 24 26 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 121 123 121 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
(A) Determination of MLD50 values. Bars indicate the genotype of the viral gene: MA-ZEBOV (red), WT-ZEBOV (blue). The MLD50 values of recombinant viruses were determined by i.p. inoculation of mice (three to six per group) with serial 10-fold dilutions of virus stock and then monitoring of survival rates. Experiments were carried out in duplicate.
###end p 110
###begin p 111
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 363 365 363 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 827 828 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
(B) Determination of the mean time to death and dose ranges causing morbidity/mortality. The mean time to death of mice inoculated with 10 FFU (approximately 1,000 MLD50 for MA-ZEBOV) are indicated. Differences in the mean time to death for mice infected with various mutants, compared to that of mice infected with MA-ZEBOV, were considered significant when the p-value was <0.05. The dose range for morbidity/mortality was determined by inoculating groups of six to nine mice with the indicated amounts of viruses and monitoring the mice for weight loss and time to death. Survival numbers (dead/total) are color-coded to indicate the severity of infection in infected mice: no disease (black), illness without mortality (green), less than or equal to 50% mortality (purple), greater than 50% mortality (red). *Dead/total. **p < 0.05.
###end p 111
###begin title 112
###xml 49 53 <span type="species:ncbi:10090">Mice</span>
Growth Characteristics of Recombinant Viruses in Mice
###end title 112
###begin p 113
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b036">36</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
Groups of 12 mice were inoculated i.p. with 5 FFU (approximately 500 LD50 values for MA-ZEBOV) of representative viruses. On days 1, 2, 3, and 5 postinoculation, selected organs were removed from three infected animals per group. Virus titers in serum (A), spleen (B) and liver (C) were determined in Vero E6 cells by using a focus-forming assay [36].
###end p 113
###begin title 114
###xml 10 16 <span type="species:ncbi:10090">Murine</span>
###xml 65 70 <span type="species:ncbi:10090">Mouse</span>
Effect of Murine Type I IFNs on Recombinant Virus Replication in Mouse Macrophages
###end title 114
###begin p 115
###xml 464 466 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020073-b036">36</xref>
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
###xml 159 165 <span type="species:ncbi:10090">murine</span>
###xml 235 241 <span type="species:ncbi:10090">murine</span>
RAW 264.7 cells (mouse peritoneal macrophage-derived cell line) were infected with a multiplicity of infection of 0.05. Cells were untreated (A), treated with murine IFN-alpha/beta (500 units/ml) 2 h postinfection (B), or treated with murine IFN-alpha/beta (500 units/ml) 12 h prior to and again 2 h after virus adsorption (C). Supernatants were collected on days 0, 1, 2, 3, and 4 postinfection and titrated by use of a focus-forming unit assay in Vero E6 cells [36].
###end p 115
###begin p 116
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 116
###begin p 117
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by grants-in-aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology, CREST (Japan Science and Technology Agency), US Public Health Service Research grants from the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institutes of Health (NIH)/NIAID Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) Program. The authors acknowledge membership within and support from the Region V "Great Lakes" RCE (NIH award 1-U54-AI-057153). Further support came from the Public Health Agency of Canada and the Canadian Institutes of Health Research (MOP-43921).
###end p 117

